PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 198 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes June 3, 2022 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... September 7, 2022 FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma February 12, 2021 Load more HOT NEWS A peek behind the scenes: Just how are our funding decisions... New lung cancer treatment combo approved on NHS in England EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail...
